Navigation Links
CEL-SCI Corporation Releases Letter to Shareholders
Date:7/7/2009

e III endpoint is substantially smaller than the 33% increase seen in Phase II.
  • No toxicity issues have been identified.
  • No safety issues have been identified.
  • Clear unmet medical need.
  • FDA granted Multikine Orphan Drug status in the USA.

  • Our clinical success would be huge since Multikine would be on course to become the recommended first-line treatment for head and neck cancer. From there, we could hopefully prove that Multikine is likely to work against other solid tumors as well.

    Our ultimate goal in development is to provide patients and physicians with a new and better way of fighting cancer. We believe that the key to doing so lies in our immune system. Dendreon's prostate cancer vaccine recently established that this is possible. Their success is even more impressive because they focused on late-stage cancer patients. We believe that Multikine should have an even greater chance of success because we focus on patients not yet treated for their cancer. Their immune system is still intact, except in the area of the tumor, and their lymphatics have not yet been cut, meaning that they can still deliver immune cells from the local lymph nodes to the tumor.

    From here on there is only one thing to do. We will launch the Phase III study as quickly as possible. Success would be phenomenal, and we anticipate that it should enable rapid approval around the world.

    We thank you for your continued support.

    Sincerely,

    Geert Kersten

    Chief Executive Officer

    When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected.
    '/>"/>

    SOURCE CEL-SCI Corporation
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. CEL-SCI to Present at the Noble Financial Conference
    2. CEL-SCI CORPORATION Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter
    3. CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
    4. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
    5. CEL-SCI Takes Delivery of New Manufacturing Facility
    6. Updated Pictures of CEL-SCI Manufacturing Facility Available Online
    7. CEL-SCI Corporation Releases Letter to Shareholders
    8. CEL-SCI Corporation Announces 2008 Financial Results
    9. CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products
    10. CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease
    11. CEL-SCIs L.E.A.P.S. Technology Shows Potential to Treat Swine Influenza in Preclinical Studies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... AudioNotch is the internet's leading provider of Notched ... tinnitus. Patients listen to sound therapy that is tailor-made ... weeks to months, their tinnitus volume decreases. , AudioNotch has ... and Notched White Noise. Now, AudioNotch is pleased to announce ...
    (Date:1/14/2014)... (PRWEB) January 14, 2014 Histogen, Inc., ... products of cells grown under simulated embryonic conditions, today ... agreement with Suneva Medical, Inc. for physician-dispensed aesthetic products ... , This agreement is an amendment to the ...
    (Date:1/14/2014)... The largest international professional organization of scientists ... derivatives thereof has endorsed an educational program that ... challenges of adulterated herb and botanical products. ... The Society for Medicinal Plant and Natural Product ...
    (Date:1/14/2014)... Mass. , Jan. 14, 2014  RXi Pharmaceuticals ... discovering, developing and commercializing innovative therapies addressing major ... that it received the Notice of Allowance from ... its unique self-delivering RNAi compounds (sd-rxRNA®), for the ...
    Breaking Biology Technology:Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
    ... who hope to create quantum computers are currently investigating ... diamond show promise for encoding quantum bits (qubits), but ... extremely weak signal. Now physicists have demonstrated a roundabout ... sorts of qubits. Their experiment is reported in the ...
    ... ... Proprietary PatentRatings® System,World’s Most Inventive Companies Are Ranked Based on Patent Quality, Not Quantity ... Chicago, IL ... announced the results of a proprietary study performed for Bloomberg BusinessWeek. , , , ...
    ... , Jan. 19 HistoRx, Inc. ... Carroll to the newly created position of Vice President, ... years of sales, marketing, research, and general management experience in ... in 2009, he was Vice President of Clinical Research for ...
    Cached Biology Technology:Turning down the noise in quantum data storage 2Ocean Tomo Study Ranks Top 25 Most Inventive Companies for Bloomberg BusinessWeek, 2Ocean Tomo Study Ranks Top 25 Most Inventive Companies for Bloomberg BusinessWeek, 3Ocean Tomo Study Ranks Top 25 Most Inventive Companies for Bloomberg BusinessWeek, 4HistoRx Names Dick Carroll, Ph.D. as VP of Clinical Research 2HistoRx Names Dick Carroll, Ph.D. as VP of Clinical Research 3
    (Date:4/24/2014)... they often inject harmful proteins into the host ... However, in some plants, bacteria attack once they,ve ... Now, researchers at the University of Missouri have ... bacteriaknown mostly for attacking tomatoesto invade its host. ... that work with food-producing plants to enhance resistance ...
    (Date:4/24/2014)... a commercially important sugar used as a sweetener, ... for synthesizing riboflavin and several antiviral drugs. Genetic ... the bacteria,s ability to produce D-ribose is a ... of this valuable chemical, as described in an ... journal from Mary Ann Liebert, Inc., publishers. The ...
    (Date:4/24/2014)... Entomological Society of America (ESA) is very pleased to ... Journal of Insect Science from the University of ... is an international, open-access, peer-reviewed journal that ... insects and other arthropods -- from the molecular to ... medical impacts. It is freely available to individuals and ...
    Breaking Biology News(10 mins):Plants send out signals attracting harmful bacteria, MU study finds 2ESA to publish the Journal of Insect Science 2
    ... steps for controlling plant growth, Australian researchers have shown ... wall regulates growth of root hairs. Root hairs are ... and water from the soil. The research will assist ... industries such as, agriculture, horticulture and forestry. ...
    ... When Hansel and Gretel ventured into the forest, ... way home. In today,s world, cellular phones, Global Positioning ... that connect us to friends, family, and colleagues while ... Yet, despite the ubiquity of such devices, with ...
    ... The world,s first three-dimensional plasmon rulers, capable ... have been developed by researchers with the U.S. ... (Berkeley Lab), in collaboration with researchers at the ... could provide scientists with unprecedented details on such ...
    Cached Biology News:Not just another brick in the (plant cell) wall 2Wireless 'breadcrumbs' that won’t become toast when baked...or soggy when hosed 2Wireless 'breadcrumbs' that won’t become toast when baked...or soggy when hosed 3Taking the 3-D measure of macromolecules: 2Taking the 3-D measure of macromolecules: 3
    ...
    ...
    Cell Lysis Buffer is used to lyse cells under nondenaturing conditions....
    Rad 50 Immunogen: c-terminal mRad 50 (604 amino acids). Storage: 4 C...
    Biology Products: